Our findings suggest that ApoA5 plays a protective role in lipid disorder and NAFLD, and provide a new insight into the development of therapeutic approaches to treat ApoA5-deficient patients with HTG and NAFLD. This evidence concerns the gene APOA5 and metabolic dysfunction-associated steatotic liver disease.